H.C. Wainwright Rates Palvella Therapeutics as a Buy
H.C. Wainwright initiates coverage on Palvella Therapeutics, citing growth potential of its lead biotech product. Explore its promising sales prospects.
H.C. Wainwright initiated coverage of Palvella Therapeutics with a Buy rating, highlighting its lead product's sales potential.